HUTCHMED (China) vs OPKO Health
HCM and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and OPK compare
OPKO Health grew revenue faster over the last twelve months (−8.3% versus −13.0% for HUTCHMED (China)).
HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −29.5% at OPKO Health.
OPKO Health scores higher on the StockData Score (8 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | OPK |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.3B |
| Share price | $14.90 | $1.68 |
| Change, 1 year | −2.5% | 27.3% |
| Change, 5 years | −51.5% | −61.4% |
| Beta (5Y) | 0.97 | 0.92 |
| Employees | 109 | 2,275 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.5× |
| P/B | – | 1.1× |
| FCF yield | – | −10.8% |
| Fair value | – | $2.10 |
| Margin of safety | – | 20.0% |
| Growth | ||
| Revenue growth (TTM) | −13.0% | −8.3% (better) |
| Revenue growth, 5Y average | 19.2% (better) | −15.8% |
| Net income growth (TTM) | 1111% | – |
| EPS growth (TTM) | 1200% | – |
| Profitability | ||
| Gross margin | 38.7% | 56.6% (better) |
| Operating margin | −7.1% (better) | −17.5% |
| Net margin | 83.3% (better) | −29.5% |
| FCF margin | −14.4% (better) | −27.0% |
| Return on equity | 36.7% (better) | −12.2% |
| Return on invested capital | – | −8.5% |
| Financial health | ||
| Debt / equity | 0.09 | 0.00 (better) |
| Interest coverage | −13.7× | – |
| Current ratio | 5.64 (better) | 4.97 |
| Altman Z-score | – | −0.28 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | – | 3.3% |
| Shareholder yield | – | 3.3% |
| Ownership | ||
| Held by institutions | 0.51% | 27.2% |
| Held by insiders | 0.44% | 43.6% |
| Insider net buying, 12 months | – | −$13.2K |
| Short interest, % of float | – | 7.8% |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- OPK stock overview
- OPK income statement
- OPK valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.